Comparison
Both are melanocortin receptor agonists derived from α-MSH research, but PT-141 was specifically developed to isolate sexual function effects while Melanotan II also stimulates skin pigmentation and has broader receptor activity.
| Attribute | PT-141 (Bremelanotide) | Melanotan II |
|---|---|---|
| Full name | Bremelanotide (PT-141) | Melanotan II (MT-II) |
| Class | Melanocortin receptor agonist — MC4R selective | Melanocortin receptor agonist — MC1R/MC3R/MC4R (non-selective) |
| Mechanism | Primarily MC4R agonism in the CNS → sexual arousal and erectile response via CNS pathway (not vascular) | MC1R (tanning/pigmentation), MC3R (energy homeostasis), MC4R (sexual function, appetite suppression) |
| Half-life | ~2.7 hours | ~1 hour |
| Commonly reported doses | 0.5–1.75 mg SubQ or intranasal (approved at 1.75 mg) | 0.025–0.5 mg SubQ (titrated; lower doses common to minimise side effects) |
| Routes | SubQ injection, intranasal (approved form) | SubQ injection |
| Primary reported use | Female hypoactive sexual desire disorder (FDA-approved as Vyleesi); male sexual dysfunction research | Tanning/skin pigmentation research; sexual function (secondary); appetite suppression |
Receptor selectivity is the defining structural distinction between these two compounds. PT-141 (bremelanotide) was developed specifically from Melanotan II research with the goal of isolating MC4R agonism while reducing MC1R activity — which directly minimises skin pigmentation effects. Melanotan II, by contrast, is non-selective across the melanocortin receptor family and activates MC1R, MC3R, and MC4R simultaneously. MC1R activation in melanocytes drives melanogenesis and tanning, an effect that is largely absent with PT-141 at commonly reported doses.
Approval status represents a significant practical distinction. PT-141 (bremelanotide) is FDA-approved under the brand name Vyleesi at a dose of 1.75 mg intranasal for the treatment of hypoactive sexual desire disorder in premenopausal women. This makes it the only melanocortin agonist with a regulatory pathway in any jurisdiction as of the knowledge cutoff. Melanotan II has no regulatory approval anywhere in the world and has no active approval pathway; all research and use involving MT-II is entirely investigational and outside any regulatory framework.
Side effect profile reflects the receptor non-selectivity of Melanotan II. Reported side effects in research and anecdotal accounts include more pronounced nausea (often described as severe, particularly at the start of use), facial flushing, and spontaneous erections in males at research doses — effects attributable to the broader receptor activation. PT-141 at commonly reported and approved doses has a more manageable reported side effect profile, with nausea, flushing, and transient blood pressure increases described as milder and more predictable. The non-selectivity of MT-II makes dose control considerably more challenging, as titrating for one receptor's effects simultaneously influences all others.
Both PT-141 and Melanotan II are synthetic cyclic peptide analogues derived from α-melanocyte-stimulating hormone (α-MSH), an endogenous peptide in the melanocortin system. The melanocortin receptor family comprises five subtypes (MC1R through MC5R), each with distinct tissue distribution and physiological roles. MC1R is expressed predominantly in melanocytes and governs skin and hair pigmentation. MC3R is expressed in the hypothalamus and peripheral tissues and is implicated in energy homeostasis and feeding behavior. MC4R is expressed broadly in the central nervous system and is the primary receptor mediating sexual arousal, erectile function, and appetite regulation via CNS-mediated pathways rather than vascular mechanisms.
PT-141's selective MC4R profile was engineered specifically to separate the sexual function effects of the melanocortin system from melanogenic activity. By reducing affinity at MC1R relative to MT-II, PT-141 produces CNS-mediated sexual response without the significant tanning effect. Melanotan II, as the parent compound, activates all three of MC1R, MC3R, and MC4R with relatively similar affinity, meaning that any dose producing MC4R-mediated effects simultaneously activates melanogenesis and energy-regulatory pathways.
PT-141 — Research has investigated PT-141 for its potential role in female hypoactive sexual desire disorder (HSDD), an indication for which it received FDA approval as Vyleesi. Research has also investigated PT-141 for its potential role in male erectile dysfunction via CNS pathways, offering a mechanistic distinction from phosphodiesterase inhibitors (e.g. sildenafil) which act peripherally and vasculogenically rather than centrally.
Melanotan II — Research has investigated Melanotan II for its potential role in skin pigmentation and tanning via MC1R-driven melanogenesis, sexual function via MC4R agonism, and appetite suppression via MC3R and MC4R activity in the hypothalamus. Anecdotal reports suggest improvement in tanning in individuals with low baseline melanin production, though all MT-II use remains investigational.
PT-141 — Commonly reported doses range from 0.5 to 1.75 mg administered subcutaneously or intranasally, typically approximately 45 minutes before the desired onset of effect. The FDA-approved intranasal dose is 1.75 mg. Anecdotal accounts frequently describe starting at lower doses (0.5–1 mg) to assess tolerance before titrating upward.
Melanotan II — Commonly reported doses in research and anecdotal contexts begin at 0.025–0.1 mg with slow upward titration due to the pronounced nausea risk at higher doses. Many anecdotal accounts describe a loading phase with gradual dose escalation over several days or weeks before reaching a maintenance dose of 0.1–0.5 mg. Starting doses in the 0.025–0.05 mg range are frequently recommended in practitioner-adjacent literature to minimise adverse effects during initial exposure.
PT-141 is administered subcutaneously or intranasally. The FDA-approved Vyleesi formulation is intranasal, delivering a fixed 1.75 mg dose. Subcutaneous administration is also commonly reported in anecdotal and research contexts. Melanotan II is administered subcutaneously only; no established intranasal or transdermal formulation exists for MT-II in the research literature. Both compounds are typically reconstituted from lyophilised powder for subcutaneous injection in non-approved research contexts.
PT-141 — Reported side effects in research and anecdotal accounts include nausea, facial flushing, transient blood pressure increases, and headache. These effects are generally described as mild to moderate and self-limiting. The FDA prescribing information for Vyleesi notes nausea as the most common reported effect and recommends antiemetic pre-treatment in some cases. Transient blood pressure elevation is also documented and represents a contraindication consideration in individuals with cardiovascular conditions.
Melanotan II — Reported side effects in research and anecdotal accounts include severe nausea (frequently described as significant, particularly at higher doses or during initial exposure), facial flushing, spontaneous or prolonged erections in males, progressive skin darkening with repeated use, yawning, and appetite suppression. The severity of nausea with MT-II is frequently cited as a limiting factor in dose escalation. Skin darkening, driven by MC1R activation, accumulates with repeated use and is reported to fade gradually after cessation, though anecdotal reports vary regarding the timeline of return to baseline pigmentation.
PT-141 — Researchers and practitioners commonly use PT-141 when the specific focus is sexual function and a regulatory-approved compound with a defined, studied side effect profile is preferred. Its MC4R selectivity and FDA-approved status make it the more directly applicable choice when the research or clinical question is narrowly concerned with sexual desire or erectile function without interest in melanogenic effects.
Melanotan II — Researchers commonly use Melanotan II when tanning or skin pigmentation is also a research variable alongside sexual function, or when the broader melanocortin receptor profile (including potential appetite suppression via MC3R/MC4R) is of investigational interest. MT-II use requires acceptance of its more complex side effect profile and the absence of any regulatory framework.
Co-administration of PT-141 and Melanotan II is not typically reported or studied. Because both compounds act on overlapping receptor populations — most critically MC4R — combining them would be pharmacologically redundant for the primary sexual function endpoint while compounding the risk of side effects. Both would compete for the same receptor targets without additive functional benefit that could not be achieved by optimising the dose of either compound individually.
In practice, researchers and practitioners choose one approach based on whether a regulatory-approved, MC4R-selective compound (PT-141) or broader melanocortin activity including melanogenesis (MT-II) is the objective. There is no established research rationale for combining the two.
Researchers commonly choose PT-141 when the focus is specifically sexual function research and a regulatory-approved compound with a well-characterised side effect profile is preferred. PT-141's MC4R selectivity means tanning effects are minimal and the pharmacological target is more precisely defined, making it the cleaner research tool for sexual function endpoints.
Researchers commonly choose Melanotan II when tanning or skin pigmentation effects are also a research variable, or when the broader receptor profile including MC3R-mediated activity is relevant to the investigational question. MT-II research requires careful dose titration and acceptance of its more pronounced side effect burden relative to PT-141, along with the understanding that it operates entirely outside any regulatory framework.
No. PT-141 was developed from Melanotan II research but differs meaningfully in receptor selectivity. PT-141 was specifically engineered to have reduced MC1R affinity relative to MT-II, which largely eliminates the skin tanning effect. PT-141 has minimal melanogenic activity at commonly reported doses, while Melanotan II causes significant and progressive skin pigmentation with repeated use. The two compounds share a common research lineage but are pharmacologically distinct.
No. Melanotan II has no regulatory approval in any jurisdiction as of the knowledge cutoff and has no active regulatory pathway. PT-141 (bremelanotide) is FDA-approved under the brand name Vyleesi for female hypoactive sexual desire disorder in premenopausal women at 1.75 mg intranasal. All Melanotan II research and use is entirely investigational and falls outside any approved or regulated framework.
Melanogenesis effects from Melanotan II use are reported to fade after cessation of use. Anecdotal reports describe a gradual return to baseline pigmentation over weeks to months following discontinuation, though individual variation is noted. The tanning effect is driven by MC1R activation of melanocytes and is dependent on continued receptor stimulation; without ongoing exposure, the melanogenic signal diminishes. No permanent structural changes to melanocyte populations have been established in available research.
Peptide Profiles